In consultation: Guidance and quality standards
Showing 1 to 10 of 10
| Title | Consultation | Type | Consultation end date |
|---|---|---|---|
| Lifileucel for previously treated unresectable or metastatic melanoma ID3863 | Draft guidance | Technology appraisal guidance | |
| Filgotinib for treating axial spondyloarthritis ID6594 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325] | Final draft guidance | Technology appraisal guidance | |
| Setmelanotide for treating acquired hypothalamic obesity in people 4 years and over ID6542 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Guidance on the use of electroconvulsive therapy | Review proposal consultation | Technology appraisal guidance | |
| Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people 1 year and over ID6400 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Pharmalgen for the treatment of bee and wasp venom allergy | Review proposal consultation | Technology appraisal guidance | |
| Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma | Review proposal consultation | Technology appraisal guidance | |
| Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy [ID6369] | Final draft guidance | Technology appraisal guidance | |
| Port Delivery platform with ranibizumab for treating wet age-related macular degeneration [ID3983] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance |